Halozyme Therapeutics (NASDAQ:HALO) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO) in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a $50.00 price objective on the biopharmaceutical company’s stock.

Several other analysts have also recently issued reports on the company. Benchmark restated a buy rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. The Goldman Sachs Group lowered their price objective on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a neutral rating for the company in a research report on Thursday, January 18th. StockNews.com raised shares of Halozyme Therapeutics from a hold rating to a buy rating in a report on Friday, February 23rd. TheStreet lowered Halozyme Therapeutics from a b- rating to a c+ rating in a report on Monday, January 22nd. Finally, JMP Securities restated a market outperform rating and set a $72.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, February 21st. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average target price of $53.29.

Halozyme Therapeutics Stock Up 0.2 %

NASDAQ HALO opened at $39.91 on Tuesday. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89. Halozyme Therapeutics has a fifty-two week low of $29.85 and a fifty-two week high of $45.00. The business has a 50 day moving average price of $39.99 and a two-hundred day moving average price of $37.89. The stock has a market cap of $5.07 billion, a PE ratio of 18.91, a P/E/G ratio of 0.46 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. The company had revenue of $230.04 million for the quarter, compared to analyst estimates of $235.25 million. As a group, sell-side analysts predict that Halozyme Therapeutics will post 3.43 EPS for the current fiscal year.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total transaction of $416,400.00. Following the sale, the senior vice president now owns 156,558 shares of the company’s stock, valued at approximately $6,519,075.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 30,000 shares of company stock valued at $1,196,800 in the last three months. 2.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Several large investors have recently bought and sold shares of the stock. Rise Advisors LLC acquired a new position in shares of Halozyme Therapeutics during the first quarter valued at approximately $25,000. Whittier Trust Co. bought a new position in Halozyme Therapeutics during the 1st quarter valued at $27,000. Principal Securities Inc. acquired a new position in shares of Halozyme Therapeutics during the 4th quarter valued at $34,000. Fidelis Capital Partners LLC acquired a new position in shares of Halozyme Therapeutics during the 1st quarter valued at $52,000. Finally, First Horizon Advisors Inc. raised its stake in shares of Halozyme Therapeutics by 24.5% in the 4th quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 293 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.